Intravenous ganaxolone for the treatment of refractory status epilepticus: Results from an open‐label, dose‐finding, phase 2 trial

• Published in: Epilepsia (Copenhagen) Vol. 63; no. 9; pp. 2381 - 2391
• Main Authors: Vaitkevicius, Henrikas, Ramsay, R. Eugene, Swisher, Christa B., Husain, Aatif M., Aimetti, Alex, Gasior, Maciej
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01-09-2022; John Wiley and Sons Inc
• Subjects: Anesthesia; Anesthetics; Anesthetics - therapeutic use; Anticonvulsants - adverse effects; antiseizure medications; Benzodiazepines; Benzodiazepines - therapeutic use; clinical trial; critical care; Dosage; Epilepsy; Humans; Intravenous administration; Neurosteroids; Patients; Pregnanolone - analogs & derivatives; seizure; Seizures; Status Epilepticus - chemically induced; Status Epilepticus - drug therapy; clinical trial; critical care; antiseizure medications; seizure; neurosteroids
• ISSN: 0013-9580; 1528-1167
• DOI: 10.1111/epi.17343

Objective
Patients with refractory status epilepticus (RSE) have failed treatment with benzodiazepines and ≥1 second‐line intravenous (IV) antiseizure medication (ASM). Guidelines recommend IV anesthesia when second‐line ASMs have failed, but potential harms can outweigh the benefits. Novel treatments are needed to stop and durably control RSE without escalation to IV anesthetics. Ganaxolone is an investigational neuroactive steroid in development for RSE treatment. This study's objective was to determine the appropriate dosing for IV ganaxolone in RSE and obtain a preliminary assessment of efficacy and safety.
Methods
This was an open‐label, phase 2 trial conducted from February 19, 2018 to September 18, 2019, at three sites in the United States. Patients were aged ≥12 years, had convulsive or nonconvulsive SE, and failed to respond to ≥1 second‐line IV ASM. Twenty‐one patients were screened; 17 were enrolled. Patients received IV ganaxolone added to standard‐of‐care ASMs. Ganaxolone infusion was initiated as an IV bolus (over 3 min) with continuous infusion of decreasing infusion rates for 48–96 h followed by an 18‐h taper. There were three ganaxolone dosing cohorts: low, 500 mg/day; medium, 650 mg/day; and high, 713 mg/day. The primary end point was the number of patients not requiring escalation to IV anesthetic treatment within 24 h of ganaxolone initiation.
Results
Most of the 17 enrolled patients (65%) had nonconvulsive SE, and had failed a median of three prior ASMs, including first‐line benzodiazepine and second‐line IV ASM therapy. Median time to SE cessation following ganaxolone initiation was 5 min. No patient required escalation to third‐line IV anesthetics during the 24‐h period following ganaxolone initiation. Two treatment‐related serious adverse events (sedation) were reported. Of the three deaths, none was considered related to ganaxolone; all occurred 9–22 days after completing ganaxolone.
Significance
IV ganaxolone achieved rapid and durable seizure control in patients with RSE, and showed acceptable safety and tolerability.